Organogenesis
Develops regenerative products for advanced wound care, surgery, and sports medicine.
Something off on this page? Send us feedback.
Profile
Sells regenerative-medicine products for advanced wound care and a smaller surgical and sports-medicine portfolio through one reportable segment. Sales lean heavily toward wound care, with execution shaped by FDA-cleared or approved products, reimbursement rules, and manufacturing transitions.
Develops and manufactures regenerative-medicine products for Advanced Wound Care and Surgical & Sports Medicine. Advanced Wound Care includes brands such as Apligraf and PuraPly; the surgical line includes NuShield, Cygnus Matrix, PuraForce, Affinity, and Novachor.
Based in Canton, Massachusetts, with employees worldwide, the business sells into hospitals, wound care centers, government facilities, ambulatory surgery centers, and physician offices. Advanced Wound Care is sold mainly through direct sales representatives; Surgical & Sports Medicine relies mainly on third-party agencies.
Execution depends on regulated biologic and device products, reimbursement coverage, and wound-care demand. Dermagraft manufacturing and distribution remain suspended pending the Smithfield, Rhode Island facility transition.
Company facts
Categories
Key statistics
Year to date −62.6% · Average volume (30d) 816.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | Truist Financial | Target | $3 | $2 | |
| May 28, 2026 | UBS | Target | $3 | ||
| May 28, 2026 | Truist Financial | Target | $3 | ||
| Nov 20, 2025 | BTIG | Reiterate | Buy | $9 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.35 | −$0.71 | −102.9% | $54.3M | $43.8M | −19.4% | −22.82% |
| May 7, 2026Q1 FY26 | −$0.29 | −$0.37 | −27.6% | $43.3M | $36.3M | −16.2% | −6.32% |
| Feb 26, 2026Q4 FY25 | $0.22 | $0.31 | +44.2% | $172.7M | $225.1M | +30.4% | −13.24% |
| Nov 6, 2025Q3 FY25 | $0.21 | $0.18 | −14.3% | $172.7M | $150.9M | −12.6% | +44.73% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $86.7M | $100.8M | $150.5M | $225.1M | $37.2M | $43.8M | |
| Gross profit | $63.0M | $73.1M | $114.2M | $175.2M | −$914.0K | $20.1M | |
| Operating income | −$20.2M | −$10.8M | $21.6M | $65.2M | −$65.0M | −$51.0M | |
| Net income | −$18.8M | −$9.4M | $21.6M | $43.7M | −$56.2M | −$99.3M | |
| Diluted EPS | −$0.17 | −$0.10 | $0.11 | $0.27 | −$0.44 | −$0.77 | |
| Gross margin | 72.6% | 72.6% | 75.9% | 77.8% | -2.5% | 45.9% | |
| Operating margin | -23.3% | -10.7% | 14.4% | 29.0% | -174.7% | -116.5% |
Fiscal years (4-quarter sums)FY21 $468.1M · FY22 $450.9M · FY23 $433.1M · FY24 $482.0M · FY25 $563.0M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $46.1M · Total debt $67.0M · Total assets $406.4M · Shareholders' equity $288.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 128.67M · Float 57.38M · 44.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Thompson Dean | 28.68M | 18.00% | 13D | Nov 19, 2024 |
| Alan A. Ades | 22.32M | 17.60% | 13D | Jun 26, 2025 |
| Morgan Stanley | 11.62M | 9.03% | 13F | May 15, 2026 |
| Soleus Capital Management, L.P. | 10.09M | 7.84% | 13F | May 14, 2026 |
| BlackRock, Inc. | 4.90M | 3.81% | 13F | May 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 9, 2026 | Michael Joseph Driscoll | director | +10,000 | $2.67 |
| Mar 9, 2026 | Arthur S. Leibowitz | director | +5,000 | $2.68 |
| Dec 16, 2025 | Glenn H. Nussdorf | director | −200,000 | $5.14 |
| Nov 26, 2025 | Glenn H. Nussdorf | director, 10 percent owner: | −187,957 | $5.29 |
| Nov 25, 2025 | Glenn H. Nussdorf | director, 10 percent owner: | −12,043 | $5.30 |
Peers
- MiMedx
Placental allograft rival in wound and surgical biologics
- Integra LifeSciences
Dermal matrices and wound reconstruction rival
- Smith & Nephew (ADR)
Global wound and sports-medicine platform rival
- Solventum
Large NPWT and advanced-dressings rival
- AVITA Medical
Acute-wound cell therapy and matrix rival
- TELA Bio
Soft-tissue reinforcement specialist rival
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Organogenesis | $1.74 | +0.29% | $223.9M | — | — | 0.5 | −56.7% |
| MiMedx | $4.50 | +0.22% | $655.9M | 112.5 | 91.3 | 1.8 | −34.7% |
| Integra LifeSciences | $16.89 | 0.00% | $1.31B | — | 6.6 | 0.8 | +0.8% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Solventum | $90.50 | −0.68% | $15.78B | 11.1 | 13.5 | 1.9 | +2.2% |
| AVITA Medical | $10.35 | +0.39% | $257.1M | — | — | 3.4 | +78.6% |
| TELA Bio | $0.7000 | +2.09% | $31.3M | — | — | 0.4 | −4.5% |
| Median | 19.2 | 13.5 | 1.9 | +1.5% |